My 2 cents. Nadar and crew are dragging us to the
Post# of 148175
The plan as I see it is to get a temporary finance mechanism in place so we can uplist in the next few weeks, just before trial data is finalized. Both resulting in a significant upward movement in price. Then, once we are at $8-10 a share they will request authorization for 25 million shares, and sell roughly 10 million to repay the financing mechanism, and the remaining 15 million will fun the 10 phase 2 trials.
We will have COVID approval by end of June, to mid July, and will be ramping up production to meet the fall wave.
Once we have COVID approval, and a clear path to revenue with no additional funding needed, we will soar to $20 a share, and the beginning of this epic ride will be underway.